Clinical trial NCT02940379: A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
Official title: A Two-cohort, Open-label, Fixed-sequence, Two-period, Two-treatment Pharmacokinetic Interaction Study of Repeated Oral Doses of Sotagliflozin on a Single Dose Cocktail of Metoprolol and Midazolam Used as Probe Substrates for CYP2D6 and CYP3A Activities, Respectively, in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2016-10-20
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary Objective:

To assess the effect of repeated once-daily oral doses of sotagliflozin on CYP2D6 and CYP3A activities using a CYP probe cocktail of metoprolol and midazolam.

Secondary Objective:

To assess the clinical and laboratory safety of sotagliflozin coadministered with the cocktail probes as compared to that of cocktail probes alone.

Detailed description: The total study duration per subject is up to 58 days.

Eligibility criteria: Inclusion criteria :

* Male or female healthy subjects, between 18 and 55 years of age, inclusive.
* Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m\^2, inclusive.
* Normal vital signs, electrocardiogram (ECG), and laboratory parameters
* Female subjects must use a double contraception method during the study, except if she has undergone sterilization at least 3 months earlier or is postmenopausal. The accepted double contraception methods include the use of one of the following contraceptive options: (1) condom; (2) diaphragm or cervical/vault cap; (3) spermicide in addition to the use of one of the following: a) Intrauterine device (IUD); b) Vasectomized partner; c) Sexual abstinence. Hormonal contraception is NOT acceptable in this study.

Exclusion criteria:

Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.

Frequent headaches and/or migraine, recurrent nausea and/or vomiting.

* Blood donation, any volume, within 2 months before inclusion.
* Symptomatic postural hypotension.
* Presence or history of drug hypersensitivity, allergic disease or asthma diagnosed and treated by a physician.
* History or presence of drug or alcohol abuse.
* If female, pregnancy or breast-feeding.
* Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion. Any oral contraceptives during the screening period or for at least 15 days prior to the first dose of Period 1; any injectable contraceptives or hormonal intrauterine devices within 12 months prior to the first dose of Period 1; or topical controlled delivery contraceptives (patch) for 3 months prior to the first dose of Period 1.
* Any contra-indications to metoprolol, according to the applicable labeling.
* Any contra-indications to midazolam, according to the applicable labeling.
* Any consumption of citrus (grapefruit, orange, etc.) or their juices within 5 days before inclusion.
* Any history or presence of deep leg vein thrombosis or embolism or a recurrent or frequent appearance of deep leg vein thrombosis in first degree relatives (parents, siblings or children).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Assessment of midazolam pharmacokinetic (PK) parameter: Area under the curve (AUC)
timeFrame: Day 1 to Day 2 of Treatment A Period
measure: Assessment of midazolam PK parameter: AUC
timeFrame: Day 11 to Day 12 of Treatment B Period
measure: Assessment of metoprolol PK parameter: AUC
timeFrame: Day 1 to Day 3 of Treatment A Period
measure: Assessment of metoprolol PK parameter: AUC
timeFrame: Day 11 to Day 13 of Treatment B Period
Secondary outcomes:
measure: Assessment of PK parameter: maximum plasma concentration (Cmax)
timeFrame: Day 1 to Day 2 of Treatment A Period (midazolam)
measure: Assessment of PK parameter: Cmax
timeFrame: Day 11 to Day 12 of Treatment B Period (midazolam)
measure: Assessment of PK parameter: Cmax
timeFrame: Day 1 to Day 3 of Treatment A Period (metoprolol)
measure: Assessment of PK parameter: Cmax
timeFrame: Day 11 to Day 13 of Treatment B Period (metoprolol)
measure: Assessment of PK parameter: time to reach Cmax (Tmax)
timeFrame: Day 1 to Day 2 of Treatment A Period (midazolam)
measure: Assessment of PK parameter: Tmax
timeFrame: Day 11 to Day 12 of Treatment B Period (midazolam)
measure: Assessment of PK parameter: Tmax
timeFrame: Day 1 to Day 3 of Treatment A Period (metoprolol)
measure: Assessment of PK parameter: Tmax
timeFrame: Day 11 to Day 13 of Treatment B Period (metoprolol)
measure: Assessment of PK parameter: terminal-half life (t1/2z)
timeFrame: Day 1 to Day 2 of Treatment A Period (midazolam)
measure: Assessment of PK parameter: t1/2z
timeFrame: Day 11 to Day 12 of Treatment B Period (midazolam)
measure: Assessment of PK parameter: t1/2z
timeFrame: Day 1 to Day 3 of Treatment A Period (metoprolol)
measure: Assessment of PK parameter: t1/2z
timeFrame: Day 11 to Day 13 of Treatment B Period (metoprolol)
Other outcomes:
Locations:
city: Knoxville
country: United States
facility: Investigational Site Number 840001
state: Tennessee
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References: